On March 21st, 2022 Tempus announced the launch of Edge, “an innovative platform that allows pathologists to access developing AI models intended to identify specimens with potentially actionable biomarkers using a single hematoxylin and eosin stain (H&E) slide”. In their press release, PathNet CEO, Dr. Matthew Leavitt, explained:
“This collaboration will carefully validate safe-use clinical applications of Tempus Histogenomics, directly comparing these algorithms with conventional ancillary testing methodologies while seeking to empower our pathologists with computational tools that can assist in identifying patients most likely to benefit from new therapies.”
Abdul Hamid Halabi, GM and SVP of Translational AI at Tempus, elaborated by saying:
“This platform will bring actionable AI to pathologists’ fingertips and support them in identifying optimal therapeutic paths for patients, while also facilitating the discovery of new biomarkers for researchers developing new, targeted therapies.”
For more information about the Edge Platform, see the full press release from Tempus.